Over 150 000 people who had TB in South Africa in 2018 were not diagnosed, according to findings from South Africa’s long-awaited National Tuberculosis Prevalence Survey. One reason for this is that an unexpectedly high number of people do not show the typical TB symptoms and are never x-rayed. Amy Green reports.
While likely millions of people in South Africa have latent tuberculosis (TB) infection, only between three and 10% of these people ever fall ill with TB. Cutting-edge research conducted in South Africa has now taken us a significant step closer to a test that can predict who will and who will not fall ill with TB. Such a test, if simple and affordable, could potentially revolutionise TB prevention efforts.
In recent months, the world has seen unprecedented investment in new vaccines. Yet, while a COVID-19 vaccine proven to be safe and effective may be less than a year away, a new tuberculosis vaccine might only be ready to be rolled out in a decade, despite a massive head start over COVID-19. Amy Green takes a closer look at the race for a new vaccine for the world’s top infectious disease killer.
We were told the planned release date for an occupational health policy to protect healthcare workers was World tuberculosis Day, 24 March 2017. Three World TB Days later and with a new epidemic claiming the lives of healthcare workers we are still waiting for the policy, writes Dr Arne von Delft.
The use of the BCG vaccine for an unproven indication is irresponsible and may deplete BCG stocks for young children, for whom it has been proven to be a lifesaving preventive tool against TB, argue a group of leading experts.
South Africa’s extensive COVID-19 response is already impacting the fight against tuberculosis (TB) with a decline in TB testing and at least one TB ward being turned into a COVID-19 ward.
This week researchers, policymakers and activists gathered in Hyderabad, India for the world’s leading TB conference. We picked six of the week’s most important stories.
